AsianScientist (Oct. 3, 2014) – Japanese pharmaceutical giant Takeda Pharmaceutical has formed a partnership with BioMotiv, the therapeutic accelerator company associated with The Harrington Project for Discovery & Development, to identify and develop pioneering medical innovations.
The initial investment is about US$2.3 million over five years, and includes exclusive rights relating to programs sourced by BioMotiv specifically in the therapeutic areas of immunology & inflammation and cardio-metabolic Diseases.
Launched in 2012, The Harrington Project for Discovery & Development is a US$250 million initiative comprising the not-for-profit Harrington Discovery Institute and BioMotiv, a for-profit therapeutic accelerator. The initiative aims to identify, fund and rapidly advance the development of medical breakthroughs from research institutions and disease foundations, throughout the USA.
“This strategic relationship with Takeda provides for a seamless continuum of expertise to aggressively advance physician-scientist derived therapeutic innovations through proof of concept and into clinical development and eventual commercialization,” commented Mr. Baiju Shah, chief executive officer of BioMotiv.
“If we truly want to deliver medical breakthroughs to patients for whom therapeutic options are currently limited, or absent, it is vital to forge these close relationships among innovators, expert resources and pharmaceutical companies at the earliest opportunity.”
Dr. Tetsuyuki Maruyama, General Manager of Takeda’s Pharmaceutical Research Division added that participation in the Harrington Project offers Takeda an opportunity to stay closely connected to physician-patient dialogue.
“Takeda has a long and rich history of therapeutic innovation and we are driven by the unmet medical needs of patients,” he said. “We are delighted to add BioMotiv to our growing list of partners.”
——-
Source: Takeda.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.
